IGM Biosciences Inc
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer and autoimmune and inflammatory diseases. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California. As of August 14, 2025, IGM Biosciences, In… Read more
IGM Biosciences Inc (IGMS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.503x
Based on the latest financial reports, IGM Biosciences Inc (IGMS) has a cash flow conversion efficiency ratio of -0.503x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-50.79 Million) by net assets ($100.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
IGM Biosciences Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how IGM Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
IGM Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of IGM Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AQUILA ACQ.CORP. CL.A
F:T81
|
N/A |
|
Hanla IMS Co. Ltd
KQ:092460
|
0.030x |
|
AME Elite Consortium Bhd
KLSE:5293
|
0.099x |
|
Rane Holdings Limited
NSE:RANEHOLDIN
|
0.044x |
|
Cantargia AB
ST:CANTA
|
0.943x |
|
Kish Bancorp Inc
OTCQX:KISB
|
0.037x |
|
K-Fast Holding AB (publ)
ST:KFAST-B
|
0.004x |
|
ZHOU HEI YA HLDG -000001
F:ZHY
|
N/A |
Annual Cash Flow Conversion Efficiency for IGM Biosciences Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of IGM Biosciences Inc from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $48.17 Million | $-153.00 Million | -3.176x | -235.78% |
| 2023-12-31 | $203.23 Million | $-192.23 Million | -0.946x | -4542.25% |
| 2022-12-31 | $287.26 Million | $-5.85 Million | -0.020x | +95.99% |
| 2021-12-31 | $244.91 Million | $-124.34 Million | -0.508x | -188.02% |
| 2020-12-31 | $381.81 Million | $-67.30 Million | -0.176x | +6.14% |
| 2019-12-31 | $240.23 Million | $-45.12 Million | -0.188x | -161.68% |
| 2018-12-31 | $-65.83 Million | $-20.04 Million | 0.304x | +19.08% |
| 2017-12-31 | $-40.50 Million | $-10.36 Million | 0.256x | -- |